Devoted Health Valuation Hits $25 Billion With $1.18B Series G

From rumor to signed deal in six weeks

In August, reports said Devoted Health was in talks to raise money at a $25 billion valuation. By October 1 the deal was done. Devoted is a Medicare Advantage insurer that also runs its own medical group. It announced a financing package of about $1.18 billion, led by Advent International with Temasek, Singapore's state-owned investment firm, as co-lead11. The price matches the figure first reported in August, when people familiar with the talks described a jump from a $16 billion valuation set earlier in the year25.

The headline number is a little misleading, though. Only $555 million is new Series G money going to the company. The other $622 million is a commitment from the same investors to buy shares from existing holders through a tender offer, which is expected to close later in the fourth quarter2014. In other words, more than half of the "$1.2 billion raise" is a liquidity event for early backers and employees, not money for Devoted to spend. Some coverage reported the round as $1.2 billion27. Trackers that went back to the company's release used the $555 million primary figure as the round size17. The second reading is the right one.

How fast the valuation climbed

Devoted's valuation history is uneven. In October 2021 the company raised a Series D of roughly $1.15 billion, led by SoftBank Vision Fund 2 and Uprising, at a post-money valuation of about $12.7 billion13. It then stayed near that level for almost three years. The December 2023 Series E priced the company at roughly $12.87 billion, and an August 2024 extension kept it at about $13 billion13.

The big move has come in the past year. In November 2025 and January 2026, Devoted raised a combined $366 million in Series F and Series F-Prime tranches, led by The Space Between in partnership with Centricus13. Reports of that round's valuation vary a little: $16 billion in the August coverage, $16.1 billion in one industry newsletter, and $16.3 billion in a data-provider listing12. Whichever figure is used, the step up to $25 billion is more than 50% in about eight months22. One weekly venture roundup put it at roughly double the January mark, which overstates the jump27.

The investor list changed, too. One analyst compared the Series F and Series G announcements and found that thirteen Series F backers did not appear in the new round, including GV, Morgan Health, General Catalyst and Frist Cressey Ventures. That doesn't necessarily mean anyone has turned against the company. The secondary sale is large, and some earlier holders may be selling rather than buying more. Still, a lead investor that is mostly a private-equity firm, joined by a sovereign wealth fund, is a different kind of backer from the venture firms behind the first several rounds. It is the kind of investor base a company builds before going public.

Growth while rivals pull back

The valuation rests mainly on enrollment, and on that measure Devoted has had an unusual year. Healthcare Dive found that during open enrollment for 2026, Devoted grew from about 210,000 members to nearly 470,000. UnitedHealthcare, CVS and Elevance were dropping hundreds of thousands of members over the same period2. Becker's put the gain at 257,000 members, or 121%, for a total of 468,00010. KFF independently counted an increase of nearly 258,000 between March 2025 and March 2026, the largest gain of any smaller insurer it tracked7.

The company now says it had about 538,000 members by September 2026, up from roughly 212,000 in December 2025. It plans to add 342 counties, which would bring it to 1,341 counties across 34 states3. Devoted also tells brokers it had the fastest percentage growth of any Medicare Advantage parent organization with more than 100,000 members between December 2025 and June 2026. It calls itself the eighth-largest carrier by CMS enrollment data8.

That growth stands out because the overall market has nearly stopped expanding. Total Medicare Advantage enrollment rose only about 3% to roughly 35.5 million, compared with historical growth that sometimes reached 10% a year2. Large insurers have been exiting markets and redesigning plans to push out unprofitable members2. Devoted has done the opposite. One analysis counted its plan offerings rising from 60 in 2022 to 427 in 2026, with about a third of its portfolio in newly launched plans, the highest share among the carriers compared6. Put simply, Devoted is picking up the members that incumbents are letting go.

Profitability, with caveats

For investors, the most important new information in the announcement may be that Devoted is profitable. Endpoints reviewed the company's state insurance (NAIC) filings and found a 1.1% profit margin in the first half of 2026, down from 2.4% a year earlier. A company spokesperson also said Devoted is GAAP profitable at the parent level, which includes the medical group and technology development.

Two cautions apply. First, a margin of about 1% leaves very little cushion in a business where one bad stretch of medical costs can wipe out a year's profit. Second, the margin fell by more than half while membership more than doubled. That fits the general pattern that new members in new markets cost more at first, but it means the profit case is not settled. Industry observers have made the same point: new money pays for expansion, but it doesn't prove the expansion will make money3.

Quality ratings, which drive Medicare bonus payments, are also mixed. For 2026, Devoted held three of the eighteen five-star contracts in the country, tied with Elevance for the most, despite being far smaller9. It has no five-star contracts for 2027, although a larger share of its members are now in plans rated four stars or higher9.

What investors are paying for

Coverage differs on why investors are willing to pay this much. The August reporting, and the outlets that repeated it, mostly pointed to artificial intelligence. They highlighted Orinoco, Devoted's in-house platform for coordinating care, as the main draw2825. One venture writer gave a more traditional explanation: because Devoted owns its medical group, it controls the medical-cost line that is hurting listed rivals27. A third view, from a health-tech analyst, is that lower administrative costs may matter more than the clinical operation, with Orinoco helping mainly on the administrative side.

The most likely answer combines the second and third views, and the "AI insurer" label is probably doing more for the marketing than for the numbers. A thin profit margin earned while membership more than doubles points to running costs and member mix, not any single breakthrough technology. Member mix may be the biggest factor of all. Devoted appears to be growing fastest in chronic-condition special needs plans (C-SNPs). KFF found that enrollment in these plans rose 45% in 2026, and that special needs plans accounted for 85% of the net growth in Medicare Advantage7. The same analyst noted that these plans tend to be much more profitable, but there is little evidence they improve patients' health or lower costs. That raises the question of whether the advantage will last if regulators look more closely.

What to watch

The deal shows what late-stage investors want right now: a company in a regulated market that is growing fast and already profitable, and that can give early shareholders a way to sell without an IPO. The $622 million secondary sale is the clearest example. Combined with the October financing, Devoted has raised nearly $3.8 billion over ten rounds, according to one tracker12. That would make it the best-funded company among its startup peers.

The risks have grown along with the price. Medicare Advantage already faces scrutiny over overpayments driven by inflated risk scores, insurers' use of algorithms, and narrow provider networks2. As Devoted gets bigger, it will lose some of its outsider image. Backing from a foreign sovereign wealth fund could also give critics in Washington something to point to. CMS also expects the average monthly Medicare Advantage premium to fall from $14.37 in 2026 to about $12 in 2027, so competing on price alone will get harder3.

The $25 billion price assumes that Devoted can keep a thin profit while serving about 1,300 counties, including many it entered within the last two years. Investors have paid for that bet up front, and the next two enrollment cycles will show whether it holds.